A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.6088
Abstract: 6088Background: CABO is a multi-tyrosine kinase inhibitor targeting VEGF receptor kinase, RET, MET and AXL. We previously participated in a Phase I study which suggested activity in the RAI-refract... read more here.
Keywords: phase; cabo; rai; cabozantinib cabo ... See more keywords